A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Open to people ages 18 years and up

1. Adult subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
2. Arm A (CC-90009 + venetoclax/azacitidine):
3. Newly diagnosed AML and is ≥ 75 years of age or intensive chemotherapy ineligible OR
4. Refractory AML and is ≥ 18 years of age
5. Arm B (CC-90009 + gilteritinib):
6. Subject is ≥ 18 years of age.
7. FLT3-ITD positive relapsed or refractory AML.
8. Gilteritinib treatment naïve
9. Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
10. Subject must have the following screening laboratory values:

11. Total White Blood Cell count (WBC) < 25 x 10⁹ prior to study treatments. Treatment with hydroxyurea to achieve this level is allowed.

12. Selected electrolytes within normal limits or correctable with supplements.
13. Participant must have adequate liver function as demonstrated by: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) and bilirubin ≤ 1.5 x ULN
14. Participant has adequate renal function as demonstrated by an estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation.
15. Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP) and combination agents' requirements.

1. Subject with acute promyelocytic leukemia (APL)
2. Subject has received systemic anticancer therapy (including investigational therapy) or radiotherapy < 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment
3. Patients with prior autologous hematopoietic stem cell transplant (HSCT) who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant related side effects)
4. Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing
5. Subject on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted
6. Subject has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2
7. Subject has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is
8. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
9. Left ventricular ejection fraction (LVEF) < 45% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO).
10. Complete left bundle branch or bifascicular block.
11. Congenital long QT syndrome.
12. Persistent or clinically meaningful ventricular arrhythmias.
13. QTcF ≥ 470 ms (Arm A) or > 450 ms (Arm B) on Screening electrocardiogram (ECG)
14. Unstable angina pectoris or myocardial infarction ≤ 6 months prior to starting study treatments or unstable arrhythmia.
15. Cardiovascular disability status of New York Heart Association Class ≥2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.

suspected during screening.

1. Subject is a pregnant or lactating female
2. . Additional exclusion criteria based on combination agent:
3. For Combination Arm A (venetoclax/azacitidine):
4. Received strong or moderate CYP3A inhibitors or inducers or P-gp inhibitors within 7 days prior to initiation of first venetoclax dose.
5. Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to first venetoclax dose through last dose of venetoclax.